CROI 2007 Wrap-Ups: Clinicians Discuss Highlights

Listen to any of these podcasts individually or download a compilation podcast (58 min.) of select CROI 2007 wrap-up interviews.

Judith Aberg, New York University at Bellevue Hospital Center
Dr. Aberg discusses new research on drugs in development, as well as lipoatrophy data from the ACTG 5142 efavirenz-vs.-lopinavir/ritonavir study
Listen to interview  (1.5MB MP3, 3.5 min.)
Read interview

Wayne Duffus, University of South Carolina School of Medicine
Dr. Duffus discusses studies that found that breastfeeding is preferable over formula for HIV-infected mothers in developing countries
Listen to interview  (1.7MB MP3, 4 min.)
Read interview

Marshall Glesby, Weill Medical College of Cornell University
Dr. Glesby recounts studies on advanced fibrosis among people with acute hepatitis C; an unexpected drug-drug interaction between rosuvastatin and lopinavir/ritonavir; and the possible anti-HIV activity of the hepatitis B drug entecavir
Listen to interview  (2.5MB MP3, 6 min.)
Read interview

Howard Grossman, Former Executive Director of the American Academy of HIV Medicine, Now Clinical Trainer in Resource-Limited Countries
Dr. Grossman discusses research on new integrase inhibitors and entry inhibitors, the safety of breastfeeding in developing countries, what's behind the rising incidence of sexually transmitted diseases among men who have sex with men, and the importance of making resistance testing available globally
Listen to interview  (7MB MP3, 17 min.)
Read interview

Trudy Larson, University of Nevada School of Medicine-Reno
Dr. Larson discusses the reversal of the breast feeding recommendations for HIV-infected women in developing countries as well as HIV drug resistance in women given a single dose of nevirapine to prevent mother-to-child HIV transmission
Listen to interview  (4.4MB MP3, 10.5 min.)
Read interview

Michael Mugavero, University of Alabama-Birmingham
Dr. Mugavero and Dr. David Wohl discuss a plenary talk by Matthais Egger comparing the outcomes of antiretroviral therapy in developed vs. developing countries, as well as a study comparing outcomes of therapy in U.S. rural vs. urban areas
Listen to interview  (4.2MB MP3, 10 min.)
Read interview

Padmini Srikantiah, University of California-San Francisco
Dr. Srikantiah comments on developing-world research: the benefits of breastfeeding, the emergence of HIV drug-resistance data, and long-term HIV treatment outcomes
Listen to interview  (1.4MB MP3, 3.5 min.)

David Wohl, University of North Carolina-Chapel Hill
Dr. Wohl discusses surprising lipid and body-shape data from ACTG 5142 (efavirenz vs. lopinavir/ritonavir); important malignancy data from the D:A:D study; and research highlighting the need for expanded HIV testing in the U.S.
Listen to interview  (3.1MB MP3, 7.5 min.)
Read interview

Benjamin Young, University of Colorado, Denver ID Consultants at Rose Medical Center
Dr. Young discusses racial and ethnic disparities in HIV transmission, care and drug toxicities
Listen to interview  (5.3MB MP3, 13 min.)
Read interview

Drugs in Development

Results of BENCHMRK-1 and BENCHMRK-2, Phase III Studies Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients With Triple-Class Resistant Virus
David Cooper, University of New South Wales, summarizes BENCHMRK-1. Roy Steigbigel, State University of New York-Stony Brook, summarizes BENCHMRK-2.
Listen to Dr. Cooper's and Dr. Steigbigel's study summary  (3.5MB MP3, 8.5 min.)
Read study summary
Listen to study summaries and interview with Roy Steigbigel, M.D.  (1.8MB MP3, 4.5 min.)
To view this study abstract, click here

48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in Antiretroviral Therapy-Naive Patients
Study summary by Anton Pozniak, Chelsea and Westminster Hospital, London, UK
Listen to Dr. Pozniak's study summary  (1.2MB MP3, 3 min.)
To view this study abstract, click here

The HIV Integrase Inhibitor GS-9137 Demonstrates Potent Antiretroviral Activity in Treatment-Experienced Patients
Study summary by Andrew Zolopa, Stanford University, CA
Listen to Dr. Zolopa's study summary  (1.9MB MP3, 4.5 min.)
To view this study abstract, click here

Efficacy and Safety of Maraviroc Plus Optimized Background Therapy in Viremic Antiretroviral Therapy-Experienced Patients Infected With CCR5-Tropic HIV-1: 24-Week Results of a Phase 2b/3 Study in the U.S. and Canada
Interview with Roy Gulick, Weill Medical College of Cornell University, NY
Listen to study summary and interview  (2.3MB MP3, 5.5 min.)
Read interview
To view this study abstract, click here

HIV Drug Resistance

ART Resistance, HIV-1 Tropism, and HIV-1 Subtype Among Men Who Have Sex With Men Recently Infected With HIV-1 in the U.S.: The EXPLORE Study
Susan Eshleman, Johns Hopkins University School of Medicine, Baltimore, MD, et al
Listen to study summary and interview  (2.2MB MP3, 5 min.)
Read interview
To view this study abstract, click here

Baseline Resistance to NNRTI as a Predictor of Virologic Failure in Treatment-Naive Subjects Receiving Efavirenz-Based Regimens in ACTG A5095
Daniel Kuritzkes, Brigham and Women's Hospital, Boston, MA, et al
Listen to study summary and interview  (1.9MB MP3, 4.5 min.)
Read interview
To view this study abstract, click here

HIV/HAART Complications

Effects of TH9507, a Growth Hormone Releasing Factor Analog, on HIV-Associated Abdominal Fat Accumulation: A Multicenter, Double-Blind, Placebo-Controlled Trial With 412 Randomized Patients
Steven Grinspoon, Massachusetts General Hospital, Boston, MA, et al
Listen to interview  (1.3MB MP3, 3 min.)
Read interview
Listen to Dr. Grinspoon summarize his study  (5MB MP3, 12 min.)
Read summary
To view this study abstract, click here

Factors Associated With Low Bone Mineral Density in a Large Cohort of HIV-Infected U.S. Adults: Baseline Results From the SUN Study
Turner Overton, Washington University School of Medicine, St Louis, MO, et al
Listen to study summary and interview  (2.3MB MP3, 5.5 min.)
Read interview
View poster: Download PowerPoint
To view this study abstract, click here

Survival After the First AIDS-Defining Illness and Causes of Death Before and After Potent Antiretroviral Therapy: Results From the French Hospital Database on HIV
Dominique Costagliola, Université Pierre et Marie Curie, Paris, France
Listen to study summary and interview  (3.1MB MP3, 7.5 min.)
To view this study abstract, click here

Alcohol Abuse or Dependence Is the Most Prevalent Comorbidity Among 48,384 HIV-Infected VA and California Medicaid Beneficiaries
David Zingmond, University of California-Los Angeles
Listen to study summary and interview  (4.2MB MP3, 10.5 min.)
To view this study abstract, click here

Unsuspected HIV Infection in Patients Presenting With Acute Meningitis
Kimberly Hanson, Duke University Medical Center, NC
Listen to study summary and interview  (1.2MB MP3, 3 min.)
To view this study abstract, click here

Comparison of Plasma HIV-1 RNA, CD4 Cell Count, and CD38 Expression on CD8 T Cells as Predictors of Progression to AIDS and CD4 Cell Decline Among Untreated Participants in the Multicenter AIDS Cohort Study
Alvaro Munoz, Johns Hopkins University, Baltimore, MD
Listen to study summary and interview  (2.2MB MP3, 5 min.)
To view this study abstract, click here

HIV Prevention/Testing

CROI HIV Prevention Wrap-Up
Julie Davids, Executive Director of the Community HIV/AIDS Mobilization Project (CHAMP), discusses HIV prevention research presented at CROI, including pre-exposure prophylaxis, microbicides and male circumcision
Listen to interview  (4.4MB MP3, 10.5 min.)

In the U.S., Fighting an Epidemic That Won't Die: An Interview With Harold Jaffe, M.D.
Dr. Jaffe discusses the current state of the U.S. epidemic, and what role clinicians, HIV advocates and HIV-positive people can play in fighting the ever-rising tide of HIV infection
Listen to interview  (5.7MB MP3, 13.5 min.)
Read transcript
To view this study abstract, click here
View slides from Dr. Jaffe's presentation: Download PowerPoint

Responding to Dr. Harold Jaffe: Where Has U.S. HIV Advocacy Gone?
Julie Davids, Executive Director of the Community HIV/AIDS Mobilization Project (CHAMP), argues that a lack of leadership is not the reason that U.S. HIV advocates have seemingly lost their clout
Listen to interview  (4.3MB MP3, 10 min.)
Read interview

New Frontiers in HIV Prevention: Male Circumcision and Pre-Exposure Prophylaxis in the United States
An interview with Patrick Sullivan, Ph.D., and Lynn Paxton, M.D., M.P.H.
Listen to study summary and interview  (8.3MB MP3, 20 min.)
Read interview

Update on the CONRAD Cellulose Sulfate Trial
Gustavo Doncel, CONRAD, Arlington, VA, sumarizes cellulose suflate trial
Listen to press conference  (1.7MB MP3, 4 min.)

Missed Opportunities to Identify HIV-infected Individuals in South Carolina, January 2001 to February 2006
Kristina Weis, University of South Carolina School of Medicine, Columbia, SC
Listen to study summary and interview  (2.2MB MP3, 5 min.)
To view this study abstract, click here

Implementing Routine Rapid HIV Testing in a Large Public Healthcare Facility
Judith Aberg, New York University at Bellevue Hospital Center, New York, NY
Listen to study summary and interview  (2.7MB MP3, 6.5 min.)
To view this study abstract, click here

Lifetime Risk of Acquiring HIV Lower Among Younger Men Who Have Sex With Men
Matthew Golden, University of Washington, Seattle, WA
Listen to study summary and interview  (1.5MB MP3, 3.5 min.)
Read interview
To view this study abstract, click here

Quality of Care

Disparities in Survival Attributable to Suboptimal HIV Care in the U.S.: Influence of Gender and Race/Ethnicity
Elena Losina, Massachusetts General Hospital, Boston, MA
Listen to study summary and press conference  (4MB MP3, 9.5 min.)
Read transcript
To view this study abstract, click here

Women & HIV

Atazanavir Use in Pregnancy: A Report of 33 Cases
Macky Natha, St. George's Hospital, London, UK
Listen to study summary and interview  (1.3MB MP3, 3 min.)
View poster: Download PowerPoint
To view this study abstract, click here

Copyright © 2007 Body Health Resources Corporation. All rights reserved. Podcast disclaimer